<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998438</url>
  </required_header>
  <id_info>
    <org_study_id>2011GWH1</org_study_id>
    <nct_id>NCT01998438</nct_id>
  </id_info>
  <brief_title>Prospective Trial of Tranexamic Acid in Cardiac Surgery</brief_title>
  <official_title>A Randomized Double-blinded Trial to Explore the Optimum Dose of Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hongwen Ji</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid, an antifibrinolytic drug, is wildly used in cardiac surgeries to decrease
      perioperative bleeding and allogenic transfusion. But the optimum dose of tranexamic acid is
      still unknown. We use three different doses to find which is the optimum dose of tranexamic
      acid in cardiopulmonary bypass cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Blood Loss</measure>
    <time_frame>24hrs postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Needs Allogenic Transfusion</measure>
    <time_frame>on the 7th day postoperatively</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of Reexploration for Bleeding</measure>
    <time_frame>on the 7th day postoperatively</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">955</enrollment>
  <condition>C.Surgical Procedure; Cardiac</condition>
  <arm_group>
    <arm_group_label>small dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>large dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>The loading doses were given in 15 minutes when incision.</description>
    <arm_group_label>small dose</arm_group_label>
    <arm_group_label>medium dose</arm_group_label>
    <arm_group_label>large dose</arm_group_label>
    <other_name>SINE</other_name>
    <other_name>Tranexamic Acid Injection</other_name>
    <other_name>120902</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Noncyanotic congenital heart disease patients requiring cardiac surgeries under
             cardiopulmonary bypass

          -  Rheumatic or recessive valvular disease patients requiring valvular repair or
             replacement under cardiopulmonary bypass

          -  Coronary artery disease patients requiring coronary artery bypass graft under
             cardiopulmonary bypass

        Exclusion Criteria:

          -  Non-primary and emergency cardiac surgery

          -  Disorder in coagulation function before surgery

          -  Anemia before surgery

          -  Definite liver and renal dysfunction

          -  History of stroke

          -  Pregnancy and lactation

          -  Disabled in spirit or law

          -  Fatal conditions such as cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongwen Ji, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haisong Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>November 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <results_first_submitted>January 29, 2016</results_first_submitted>
  <results_first_submitted_qc>January 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2016</results_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Hongwen Ji</investigator_full_name>
    <investigator_title>professor of medicine</investigator_title>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Small Dose</title>
          <description>10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery
Tranexamic Acid: The loading doses were given in 15 minutes when incision.</description>
        </group>
        <group group_id="P2">
          <title>Medium Dose</title>
          <description>20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery
Tranexamic Acid: The loading doses were given in 15 minutes when incision.</description>
        </group>
        <group group_id="P3">
          <title>Large Dose</title>
          <description>30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery
Tranexamic Acid: The loading doses were given in 15 minutes when incision.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
                <participants group_id="P2" count="318"/>
                <participants group_id="P3" count="318"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
                <participants group_id="P2" count="318"/>
                <participants group_id="P3" count="318"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Small Dose</title>
          <description>10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery
Tranexamic Acid: The loading doses were given in 15 minutes when incision.</description>
        </group>
        <group group_id="B2">
          <title>Medium Dose</title>
          <description>20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery
Tranexamic Acid: The loading doses were given in 15 minutes when incision.</description>
        </group>
        <group group_id="B3">
          <title>Large Dose</title>
          <description>30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery
Tranexamic Acid: The loading doses were given in 15 minutes when incision.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="319"/>
            <count group_id="B2" value="318"/>
            <count group_id="B3" value="318"/>
            <count group_id="B4" value="955"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.1" spread="10.9"/>
                    <measurement group_id="B2" value="53.2" spread="11.8"/>
                    <measurement group_id="B3" value="53.1" spread="11.6"/>
                    <measurement group_id="B4" value="53.1" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="180"/>
                    <measurement group_id="B4" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Blood Loss</title>
        <time_frame>24hrs postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Small Dose</title>
            <description>10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery
Tranexamic Acid: The loading doses were given in 15 minutes when incision.</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose</title>
            <description>20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery
Tranexamic Acid: The loading doses were given in 15 minutes when incision.</description>
          </group>
          <group group_id="O3">
            <title>Large Dose</title>
            <description>30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery
Tranexamic Acid: The loading doses were given in 15 minutes when incision.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Blood Loss</title>
          <units>ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="520" lower_limit="350" upper_limit="690"/>
                    <measurement group_id="O2" value="490" lower_limit="350" upper_limit="690"/>
                    <measurement group_id="O3" value="450" lower_limit="324.5" upper_limit="620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Needs Allogenic Transfusion</title>
        <time_frame>on the 7th day postoperatively</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rate of Reexploration for Bleeding</title>
        <time_frame>on the 7th day postoperatively</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days postoperative</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Small Dose</title>
          <description>10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery
Tranexamic Acid: The loading doses were given in 15 minutes when incision.</description>
        </group>
        <group group_id="E2">
          <title>Medium Dose</title>
          <description>20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery
Tranexamic Acid: The loading doses were given in 15 minutes when incision.</description>
        </group>
        <group group_id="E3">
          <title>Large Dose</title>
          <description>30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery
Tranexamic Acid: The loading doses were given in 15 minutes when incision.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>renal dysfunction</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="318"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>usage of IABP</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cerebral embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal dysfunction</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="319"/>
                <counts group_id="E2" events="40" subjects_affected="40" subjects_at_risk="318"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hongwen Ji</name_or_title>
      <organization>Fuwai Hospital</organization>
      <phone>+86 13701229553</phone>
      <email>jihongwen@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

